Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.